SCS Capital Management LLC Invests $480,000 in IQVIA Holdings Inc. $IQV

Key Points

• SCS Capital Management LLC has acquired a new stake of 2,720 shares in IQVIA Holdings Inc., valued at approximately $480,000, during the 1st quarter of the year.
• Insiders at IQVIA have sold significant shares, with Keriann Cherofsky and Eric Sherbet selling shares valued at over $1.2 million combined, resulting in a decrease in their respective positions.
• IQVIA recently reported quarterly earnings of $2.81 EPS, surpassing analysts' expectations, with a revenue of $4.02 billion, indicating a 5.3% year-over-year growth.

SCS Capital Management LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,720 shares of the medical research company's stock, valued at approximately $480,000.

Several other hedge funds also recently modified their holdings of IQV. Semmax Financial Advisors Inc. lifted its stake in shares of IQVIA by 8.7% in the 1st quarter. Semmax Financial Advisors Inc. now owns 19,005 shares of the medical research company's stock valued at $3,351,000 after purchasing an additional 1,518 shares during the last quarter. Empowered Funds LLC boosted its stake in shares of IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company's stock worth $1,715,000 after acquiring an additional 4,915 shares in the last quarter. MBB Public Markets I LLC bought a new position in shares of IQVIA in the 1st quarter valued at approximately $292,000. United Services Automobile Association acquired a new stake in IQVIA in the 1st quarter worth approximately $719,000. Finally, Aristeia Capital L.L.C. bought a new stake in IQVIA during the first quarter worth approximately $444,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of NYSE IQV traded up $1.06 during trading hours on Tuesday, reaching $187.03. The stock had a trading volume of 403,053 shares, compared to its average volume of 1,890,474. The business's fifty day moving average is $182.87 and its two-hundred day moving average is $167.11. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $31.80 billion, a price-to-earnings ratio of 27.03, a PEG ratio of 2.06 and a beta of 1.32. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $248.03.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the prior year, the business posted $2.64 earnings per share. The business's revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insiders Place Their Bets

In related news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of analyst reports. William Blair restated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Barclays upped their price target on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Robert W. Baird lifted their price objective on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Truist Financial raised their target price on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Finally, JPMorgan Chase & Co. cut their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Eighteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $229.64.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.